Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fructose Extra-splanchnic Metabolism and Its Effects on Systemic Flux of Substrates (FruPP) (FruPP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03195062
Recruitment Status : Completed
First Posted : June 22, 2017
Last Update Posted : October 18, 2018
Sponsor:
Information provided by (Responsible Party):
Luc Tappy, MD, University of Lausanne

Brief Summary:

In parallel to the dramatic rise in metabolic diseases and diabetes observed over the past fifty years, the generalization of added sugar in processed food led to a marked increase in fructose consumption in almost all countries, and epidemiological studies demonstrated that the consumption of sugar-sweetened beverage (containing at least 50% of fructose) is associated with the development of diabetes, hepatic steatosis, dyslipidemia and obesity.

The objective of the study is to measure the amount of fructose that escape first-pass hepatic extraction after oral ingestion (fructose+glucose), and gain insights into its metabolic fates with the use of tracers.


Condition or disease Intervention/treatment Phase
Test Meal Other: Test meal Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Fructose Extra-splanchnic Metabolism and Its Effects on Systemic Flux of Substrates (FruPP)
Actual Study Start Date : March 23, 2017
Actual Primary Completion Date : June 30, 2018
Actual Study Completion Date : August 31, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Fructose

Arm Intervention/treatment
Experimental: Test meal
The subjects will receive a liquid test meal containing glucose and fructose with 13C fructose.
Other: Test meal
Liquid test meal (fructose+glucose)




Primary Outcome Measures :
  1. Measurement of the amount of fructose that escape first-pass hepatic extraction after oral ingestion. [ Time Frame: The quantity of 13C fructose will be calculated, during the post prandial period, until 240 min. ]
    Calculation with 13C fructose enrichment in blood samples at T0; 30; 60; 90; 120; 150; 180; 210 and 240 min.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Aged from 18 to 40 years
  • Body Mass Index of 18.5 to 25 kg/m²
  • Sex male of female

Exclusion Criteria:

  • Fructose intolerance
  • Antidiabetic and hypolipemic drugs
  • Alcohol consumption >10g/day
  • Severe eating disorders
  • Severe psychological problems
  • Vegetarian diet or other specific diet
  • Consumption of illicit substances
  • Pregnancy
  • Weight gain or weight loss > 3 kg in the last 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03195062


Locations
Layout table for location information
Switzerland
University of Lausanne
Lausanne, Switzerland, 1005
Sponsors and Collaborators
University of Lausanne

Layout table for additonal information
Responsible Party: Luc Tappy, MD, MD, Professor, University of Lausanne
ClinicalTrials.gov Identifier: NCT03195062     History of Changes
Other Study ID Numbers: 2016-01828
First Posted: June 22, 2017    Key Record Dates
Last Update Posted: October 18, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Luc Tappy, MD, University of Lausanne:
Fructose
Obesity
Metabolism
Post-prandial kinetics